Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study
Gustavsson, Anders ; Raket, Lars Lau LU ; Lilja, Mathias ; Rutten-Jacobs, Loes ; Fues Wahl, Hanna ; Bagijn, Marloes ; Stomrud, Erik LU
; Hansson, Oskar
LU
and Palmqvist, Sebastian
LU
(2021)
In Alzheimer's and Dementia
17(11).
p.1832-1842
- Abstract
Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are missing, potentially delaying payer approval of treatment. We examined whether health utility, assessed with the EuroQoL-5 3-level version (EQ-5D-3L), differed between individuals with a positive or negative amyloid beta (Aβ) biomarker in patients with mild cognitive impairment (MCI) and cognitively unimpaired (CU) participants from the Swedish BioFINDER study (n = 578). Participants with prodromal AD (Aβ-positive MCI) reported better health utility (n = 79, mean = 0.81, 95% confidence interval [CI] 0.77–0.85) than Aβ-negative... (More)
Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are missing, potentially delaying payer approval of treatment. We examined whether health utility, assessed with the EuroQoL-5 3-level version (EQ-5D-3L), differed between individuals with a positive or negative amyloid beta (Aβ) biomarker in patients with mild cognitive impairment (MCI) and cognitively unimpaired (CU) participants from the Swedish BioFINDER study (n = 578). Participants with prodromal AD (Aβ-positive MCI) reported better health utility (n = 79, mean = 0.81, 95% confidence interval [CI] 0.77–0.85) than Aβ-negative MCI (mean = 0.71, 95% CI 0.64–0.78), but worse than controls (Aβ-negative CU, mean = 0.87, 95% CI 0.86–0.89). Health utility in preclinical AD (Aβ-positive CU; mean = 0.86, 95% CI 0.83–0.89) was similar to controls. This relatively good health utility in prodromal AD suggests a larger value of delaying progression to dementia than previously anticipated and a great value of delaying clinical progression in preclinical AD.
(Less)
- author
- Gustavsson, Anders
; Raket, Lars Lau
LU
; Lilja, Mathias
; Rutten-Jacobs, Loes
; Fues Wahl, Hanna
; Bagijn, Marloes
; Stomrud, Erik
LU
; Hansson, Oskar
LU
and Palmqvist, Sebastian
LU
- organization
- publishing date
- 2021-05-13
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Alzheimer's disease, health utility, modeling, outcomes, quality of life
- in
- Alzheimer's and Dementia
- volume
- 17
- issue
- 11
- pages
- 1832 - 1842
- publisher
- Wiley
- external identifiers
-
- scopus:85105618597
- pmid:33984179
- ISSN
- 1552-5260
- DOI
- 10.1002/alz.12355
- language
- English
- LU publication?
- yes
- id
- cad4b8e0-a20d-4b38-963e-55655525024e
- date added to LUP
- 2021-06-01 16:19:55
- date last changed
- 2024-04-20 07:55:22
@article{cad4b8e0-a20d-4b38-963e-55655525024e,
abstract = {{<p>Quality of life and health utility are important outcomes for patients with Alzheimer's disease (AD) and central for demonstrating the value of new treatments. Estimates in biomarker-confirmed AD populations are missing, potentially delaying payer approval of treatment. We examined whether health utility, assessed with the EuroQoL-5 3-level version (EQ-5D-3L), differed between individuals with a positive or negative amyloid beta (Aβ) biomarker in patients with mild cognitive impairment (MCI) and cognitively unimpaired (CU) participants from the Swedish BioFINDER study (n = 578). Participants with prodromal AD (Aβ-positive MCI) reported better health utility (n = 79, mean = 0.81, 95% confidence interval [CI] 0.77–0.85) than Aβ-negative MCI (mean = 0.71, 95% CI 0.64–0.78), but worse than controls (Aβ-negative CU, mean = 0.87, 95% CI 0.86–0.89). Health utility in preclinical AD (Aβ-positive CU; mean = 0.86, 95% CI 0.83–0.89) was similar to controls. This relatively good health utility in prodromal AD suggests a larger value of delaying progression to dementia than previously anticipated and a great value of delaying clinical progression in preclinical AD.</p>}},
author = {{Gustavsson, Anders and Raket, Lars Lau and Lilja, Mathias and Rutten-Jacobs, Loes and Fues Wahl, Hanna and Bagijn, Marloes and Stomrud, Erik and Hansson, Oskar and Palmqvist, Sebastian}},
issn = {{1552-5260}},
keywords = {{Alzheimer's disease; health utility; modeling; outcomes; quality of life}},
language = {{eng}},
month = {{05}},
number = {{11}},
pages = {{1832--1842}},
publisher = {{Wiley}},
series = {{Alzheimer's and Dementia}},
title = {{Health utility in preclinical and prodromal Alzheimer's disease for establishing the value of new disease-modifying treatments—EQ-5D data from the Swedish BioFINDER study}},
url = {{http://dx.doi.org/10.1002/alz.12355}},
doi = {{10.1002/alz.12355}},
volume = {{17}},
year = {{2021}},
}